Sona Nanotech, Inc. engages in the development of multiple proprietary methods for the manufacture of various types of gold nanoparticles in medical applications. It is involved in developing targeted hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The company was founded by Gerrard Marangoni, Kulbir Singh, and Michael McAlduff on November 17, 2004 and is headquartered in Halifax, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company